slide1
Download
Skip this Video
Download Presentation
Europe\'s Biotech deficit – consequences and hopes

Loading in 2 Seconds...

play fullscreen
1 / 18

Thread of infectious diseases - high death toll - PowerPoint PPT Presentation


  • 2680 Views
  • Uploaded on

Europe\'s Biotech deficit – consequences and hopes. ALEXANDER VON GABAIN . “ We cannot be a strong nation unless we are a healthy nation“. President Franklin D. Roosevelt. Thread of infectious diseases - high death toll, only part of the story. AT ANY TIME.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Thread of infectious diseases - high death toll' - flora


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Europe\'s Biotech deficit – consequences and hopes

ALEXANDER VON GABAIN

“We cannot be a strong nation unless we are a healthy nation“

President Franklin D. Roosevelt

thread of infectious diseases high death toll only part of the story
Thread of infectious diseases - high death toll, only part of the story
  • AT ANY TIME
  • Every fourth human life terminated by microbial infections
  • 13 million deaths per year in developing countries only
  • 6 million children thereof
  • Multi-drug resistant microbes in hospitals and communities
  • Novel pathogens emerge
  • Bioterrorism
  • Pandemic flu, as seen 1918, with estimated 50 million deaths
  • Approx. 100 million people disabled by infectious diseases
  • 10 millions of children kept away from school due to infections
  • Infectious diseases deform, mutilate and disable children for life
  • DALY* is the greatest burden of infectious diseases
  • Economic burden cannot be calculated

* disability adjusted life years

FOPI-EFA-Symposium

chronic infectious diseases a new paradigm in medicine
Chronic infectious diseases - a new paradigm in medicine

Are bacteria and viruses the cause of non- inhered diseases?

  • Autoimmune-diseases
  • Bacterial infections
  • Arteriosclerosis diseases
  • Neurodegenerative diseases
  • Viral infections
  • HPV, HCV, HBV, Helicobacter infections
  • Cancer

FOPI-EFA-Symposium

the vaccine field challenges ahead and new paradigms
The vaccine field: challenges ahead and new paradigms
  • FORCES AT WORK
  • No efficacious vaccines against many infectious diseases
  • Many existing vaccines do not protect important population cohorts (e.g. influenza for elderly)

"Come back of

vaccines"

  • New vaccines open a wide field to prevent and to treat diseases with unmet need; e.g. HPV-induced cervix car-cinome, nicotine-dependence
  • Combination of therapeutic vaccines and other treatments open new therapeutics against chronic viral diseases and cancer

FOPI-EFA-Symposium

growing market with a restricted number of mostly us prone vaccine players

Industry Landscape

% of market share

Growing market with a restricted number of mostly US-prone vaccine players

GLOBAL VACCINE MARKET

Traditional and combinations

US$ bn

Novel and therapeutic vaccines

21.9

16.6

11.7

  • Other
  • Sanofi-Aventis**
  • Novartis/
  • Chiron*

8.8

6.8

2.0

  • GSK

* recently acquired** strategic partners of Intercell

1990

2001

2003

2005E

2007E

2009E

Expected CAGR 2003 - 2009

  • Merck**
  • Global vaccine market 16%
  • Novel and therapeutic vaccines 38%
  • Traditional and combination 0% vaccines
  • Wyeth

Sources:Frost & Sullivan, Datamonitor, Theta Reports, Genesis, Company Information

Other: Acambis, Bavarian Nordic, Baxter, Intercell,Berna Biotech*, Corixa*, ID Biomedical*, Solvay

FOPI-EFA-Symposium

the innovation gap of the established pharma and vaccine industry a fact
The innovation gap of the established pharma and vaccine industry - a fact

Number of new FDA approved drugs

  • bn US$

Pharma R&D spending

Source: Phar-maceutical Research and Manu-factures of America, FDA, Burill & Co.

FOPI-EFA-Symposium

biotech industry provides hope majority of product pipeline comes from smaller biotech
Biotech industry provides hope: majority of product pipeline comes from smaller biotech

COMPOUNDS IN DEVELOPMENT BY COMPANY SIZE

Others (mainly biotech)

Top 100 Pharma players

69%

Number of compounds

68%

67%

31%

55%

32%

33%

45%

Source: PharmaProjects, BCG

FOPI-EFA-Symposium

europe s biotech vision or does history repeat
Europe’s biotech vision or does history repeat?
  • "In the following 10 years the Soviet Union will out-compete the capitalist economy of the USA in terms of per capita income, economic welfare, growth and high tech"
  • President Nikita Krushchev, 1963

"Until 2010 Europe will overtake the US in growth of Biotech industry“

EU Lisbon Summit, 2000

FOPI-EFA-Symposium

sobering facts speak another language
Sobering facts speak another language
  • Europe
  • US
  • Public listed biotech companiesin percent
  • Private equity investment in biotechin % of GDP
  • Origin of patents used by European biotechin percent
  • <10
  • ~0.38
  • ~28
  • >30
  • ~1.50
  • ~52

FOPI-EFA-Symposium

europe versus usa state of being behind
Europe versus USA – state of being behind
  • In US$ bn
  • Market cap (2005)
  • Revenue (2004)

Biotech Companies USA

  • Amgen
  • Genentech
  • Genzyme
  • 88.78
  • 87.86
  • 17.74
  • 10.55
  • 4.62
  • 2.20
  • Total
  • 194.38
  • 17.37

Biotech Companies Europe

  • Serono*
  • Actelion*
  • Quiagen*
  • 7.88
  • 1.98
  • 1.94
  • 2.46
  • 0.22
  • 0.96
  • Total
  • 11.80
  • 3.64

* not truly considered as Biotechs

FOPI-EFA-Symposium

underdeveloped biotech consequences for biomedical research and health care
Underdeveloped biotech - consequences for Biomedical Research and Health Care
  • Health care quality will drop: European hospitals become less and less R&D drivers (e.g. compare ratio of phase I/II to phase III/IV trials Europe versus USA)
  • Lack of job opportunities for MDs and PhDs in Europe
  • Brain drain – exodus of biomedical scientists (nearly 50% of European MD/Ph.D. scientists decide to stay in the USA 1990, today more than 70%!)
  • Biomedical research obtains less overflow from charities

FOPI-EFA-Symposium

slide13

History:Spin off from the Campus Vienna Biocenter, IMP and University 1999. Today 160 employees from 16 nations in Vienna, Edinburgh & North Carolina, USA

Partners:Merck (USA), Sanofi Aventis, SSI, Boehringer Ingelheim, SciGen, Biological E, EC, NIH, CDC, WRAIR, Karolinska, MPI, AERAS foundation

Funding:Investors include Apax, Nomura, TVM, MPM Capital, GLSV, Sal. Oppenheim & K&W. Since 2005 listed at the ATX (ICLL): Today’s Market cap: approx. € 300m

Products: Therapeutic & prophylactic vaccines based on the latest stage immunology and vaccine technology

Intercell, an international biotech vaccine player, a spin off from a Viennese University Chair

People:» Management board: G. Zettlmeissl (CEO), A. v. Gabain (CSO and founder) & W. Lanthaler (CFO)

» Supervisory board: E.G. Afting, D. Ebsworth, M. Gréco, H. Küpper,

H. Schühsler & J. Sulat

» SAB: R. Ahmed, H. Blum, S. Cohen, F.X. Heinz,

S. Kaufmann, S. Normark, H. Wigzell

FOPI-EFA-Symposium

advanced clinical programs promising product pipeline and strategic partnerships

Japanese Encephalitis(JEV) (IC51)

  • 2006
  • Hepatitis C therapeutic (IC41)
  • 2008
  • 2011

*

**

***

****

  • S. pneumoniae
  • 2006/07
  • Group A Streptococcus
  • 2006/07
Advanced clinical programs – promising product pipeline and strategic partnerships
  • PRODUCT CANDIDATES OVERVIEW

Clinical progressin last 12 month

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Filing
  • Advanced clinical product candidates
  • Product
  • Pipeline
  • Therapeutic Antibodies

S. pneumoniae; GBS

  • 2006
  • 2007
  • Travelers diarrhea
  • Tuberculosis*
  • 2006/07
  • Strategic partner-
  • ships
  • 2006
  • Hepatitis B therapeutic**
  • S. aureus***
  • 2006/07
  • Bacterial vaccine ****
  • 2006/07

FOPI-EFA-Symposium

european assets to build a robust biotech industry
European assets to build a robust biotech industry
  • High level of education
  • Solid academic base
  • Competent and good quality research at many Universities
  • Historical power-houses of research; Pasteur, Karolinska, Cambridge, Oxford, EMBO, Max Plank Institute, Basle Biozentrum, Campus Vienna Biocenter (Max Perutz lab., IMP IMBA) etc.
  • Growing number of Centers of Excellence
  • Long tradition of Pharma development
  • Excellent clinical institutions with the potential to carry out clinical research-driven studies
  • Growing interaction between the national biomedical scenes
  • Scientific output in the field of biotech is still significant

still European biotech hasn’t hit the street

FOPI-EFA-Symposium

thank you for your attention
Thank you for your attention

If you think research isexpensive, try disease

Mary Lasker (1901-1994)

FOPI-EFA-Symposium

slide18

INFLUENZA VACCINE DISTRIBUTION (40 COUNTRIES, 2002)

  • Doses of influenza vaccine distributed per 1,000 population
  • Canada
  • United States
  • Rep. of Korea
  • Australia
  • Spain
  • Belgium
  • The Netherlands
  • United Kingdom
  • Germany
  • New Zealand
  • Italy
  • Iceland
  • France
  • Japan
  • Switzerland
  • Greece
  • Finland
  • Ireland
  • Russia
  • Hungary
  • Portugal
  • Sweden
  • Denmark
  • Austria
  • Luxembourg
  • Slovak Republic
  • Slovenia
  • Norway
  • Argentina
  • Brazil
  • Poland
  • Latvia
  • Czech Republic
  • Romania
  • Lithuania
  • Bulgaria
  • South Africa
  • Mexico
  • Turkey
  • Egypt

Source: Journal of Public Health Policy

FOPI-EFA-Symposium

ad